Given the reported side effects associated with statins, the wider use of newer approaches to treat dyslipidaemia such as the PCSK-9 inhibitors and possibly, ethyl icosapent, may result in a further decrease in the CAD burden in both patient groups with and without diabetes [22]. Here, PCSK9 is linked to coronary artery disorder.